

Open Up your Science in EHJ Open

Magnus Bäck (1,2,3,*, Maciej Banach⁴, Frieder Braunschweig^{1,2}, Salvatore De Rosa (1,2, 5,4) Alessia Gimelli (1,2,3,*, Maciej Banach⁴, Frieder Braunschweig^{1,2}, Salvatore De Rosa (1,2,5) Alessia Gimelli (1,2,5) Susanna C. Larsson^{11,12}, Linda Mellbin^{1,2}, Edit Nagy^{1,2}, Gianluigi Savarese (1,2,5) Karolina Szummer^{1,13}, and Denis Wahl³; European Heart Journal Open Section Editors

¹Department of Cardiology, Karolinska University Hospital, Solna, Sweden; ²Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; ³Nancy University Hospital, University of Lorraine and INSERM U1116, Nancy, France; ⁴Department of Preventive Cardiology and Lipidology, Medical University of Lodz and Polish Mother's Memorial Hospital Research Institute, Lodz, Poland; ⁵Magna Graecia University of Catanzaro, Catanzaro, Italy; ⁶Fondazione Toscana Gabriele Monasterio, Pisa, Italy; ⁷Department of Cardiology, Danderyd University Hospital, Danderyd, Sweden; ⁸Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden ⁹Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark; ¹⁰GIGA Cardiovascular Sciences, Centre Hospitalier Universitare Sart Tilman, University of Liège Hospital, Liège, Belgium; ¹¹Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; ¹²Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; and ¹³Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

The Editorial Board of *European Heart Journal Open* (EHJ Open) has unlocked the doors to open science in cardiology—#Open UpYourScience. EHJ Open is designed to facilitate fluid and open communication between all subject sections in cardiology, with the aim of achieving open and interactive science for a broad readership (*Figure 1*). EHJ Open is an open house for all researchers, readers, practitioners, and allied professionals in cardiology. The section editors consolidate to allow an accelerated and global sharing of highquality science on all aspects of cardiovascular disease (CVD).

The first article published in EHJ Open revealed that Heart Failure (Section Editor: Gianluigi Savarese) rose to the top of the list of cardiovascular causes of hospitalizations in the USA.¹ Alongside this paper in the first issue, we present novel findings in a nationwide cohort of many millions of subjects on CVD prediction,² published in the section Epidemiology & Prevention (Section Editor: Karolina Szummer). The first EHJ Open issue in addition hosts biomarker studies from large populations identifying trimethyllysine associated with increased mortality risk³ both in the absence and presence of Coronary Artery Disease (Deputy and Section Editor: Maciej Banach). The house of EHJ Open is expanded to Vascular Medicine (Section Editor: Denis Wahl) to provide space for the entire cardiovascular system, covering the full spectrum of arterial and venous diseases, cardiovascular affection of systemic diseases, and a special focus on stroke as link between the heart and brain. The results of a European survey on the management of Hypertension (Deputy and Section Editor: Thomas Kahan) are presented in the first EHJ Open issue.⁴

The underlying *Cardiovascular Genetics* (Section Editor: Susanna Larsson) is of additional major importance for risk factor evaluation,

addressing the scientific questions on causality through Mendelian Randomization and by expanding the emerging field of cardiogenetics, which links to the section on *Arrhythmia and Electrophysiology* (*Deputy and Section Editor: Frieder Braunschweig*),


Cardiovascular Imaging (Section Editor: Alessia Gimelli) contains a tool box of advanced techniques to optimize the cardiovascular diagnostics and prediction, both at rest and during stress.⁵ The imaging section room is also accessible through several other sections, as illustrated by the novel technique four-dimensional flow magnetic resonance imaging to evaluate the cavopulmonary connection⁶ in *Adult Congenital Heart Disease* (Section Editor: Edit Nagy). The latest ESC Guidelines on the management of adult congenital heart disease pointed out the advances in this field for not only risk stratification and medical treatments but also for *Interventional Cardiology and Cardiac Surgery* (Section Editor: Salvatore De Rosa). The importance of the latter section for coronary and Valvular Heart Disease (Section Editor: Patrizio Lancellotti) will build the bridge not only between prevention and intervention in cardiology but also between surgical, interventional, and medical approaches.

Special Populations (Section Editor: Linda Mellbin) of increasing interest in cardiology traditionally focus on comorbidities in terms of diabetes and chronic kidney disease. An expanding field into also cardio-oncology⁷ and the field of sex-differences and gender dimensions in cardiology.⁸ Other special population is the elderly⁷ and the most recent special population in cardiology: coronavirus disease 2019 (COVID-19). We present in this issue the results of the randomized controlled Three C trial for canakinumab-treatment of cardiac patients with

^{*} Corresponding author. Email: magnus.back@ki.se

[©] The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com



SARS-CoV2 infection.⁹ and the invited commentary by Dr Paul M. Ridker on what we have learned from targeting cytokine storm in COVID-19.¹⁰

COVID-19 is also recognized as important topic for *Translational Basic Science* (Section Editor: Daniel Ketelhuth), in the present issue addressing the mechanistic link between SARS CoV2 vaccination and thrombotic complications.¹¹ To focus on findings allowing a rapid transfer of basic science findings into clinical practice, this section covers of a broad spectrum of translational cardiovascular research by budding into vesicles of vascular and myocardial biology as well as atherosclerosis and thrombosis (*Figure 1*).

We all gather to welcome you to our #EHJOpen house and to follow @ehjopen on Twitter and hope that you enjoy reading the first issue. We commit to our full-hearted support of the entire cardiology community to #OpenUpYourScience.

Conflict of interest: none declared.

References

- Salah HM, Khan Minhas AM, Khan MS, Pandey A, Michos ED, Mentz RJ, Fudim M. Causes of hospitalization in the United States between 2005–2018. *Eur Heart J Open* 2021.
- Christensen DM, Phelps M, Gerds T, Malmborg M, Schjerning A-M, Strange JE, El-Chouli M, Larsen LB, Fosbøl E, Køber L, Torp-Pedersen C, Mehta S, Jackson R, Gislason G. Prediction of first cardiovascular disease event in 2.9 million individuals using Danish administrative healthcare data: a nationwide, registry-based derivation and validation study. *Eur Heart J Open* 2021.
- Bjørnestad EØ, Dhar I, Svingen GFT, Pedersen ER, Svenningsson MM, Tell GS, Ueland PM, Ørn S, Sulo G, Laaksonen R, Nygård O. Trimethyllysine predicts all-

cause and cardiovascular mortality in community-dwelling adults and patients with coronary heart disease. *Eur Heart J Open* 2021.

- 4. Mancusi C, de Simone G, Asteggiano R, Richter D, Williams B, FerriniM. Survey on arterial hypertension management: a report from the ESC Council for Cardiology Practice and the ESC Council on Hypertension. *Eur Heart J Open* 2021.
- Neglia D, Aimo A, Lorenzoni V, Caselli C, Gimelli A. Triglycerides glucose index predicts outcome in patients with chronic coronary syndrome independently of other risk factors and myocardial ischemia. *Eur Heart J Open* 2021.
- Rijnberg FM, Juffermans JF, Hazekamp MG, Helbing WA, Lamb HJ, Roest AAW, Westenberg JJM, Van Assen HC.Segmental assessment of blood flow efficiency in the total cavopulmonary connection using 4D flow MRI: vortical flow is associated with increased viscous energy loss. European Heart Journal Open 2021; oeab018, 10.1093/ehjopen/oeab018.
- Roderburg C, Loosen SH, Jördens MS, Konrad M, Luedde T, Kostev K, Luedde M. Heart failure and dementia: a comparative analysis with different types of cancer. *Eur Heart J Open* 2021.
- Borrelli N, Brida M, Cader A, Sabatino J, Czerwińska-Jelonkiewicz K, Shchendrygina A, Wood A, Allouche E, Avesani M, Gok G, Marchenko O, Calvieri C, Baritussio A, Ilardi F, Caglar N, Moscatelli S, Kotlar I, Trêpa M, Rubini MG, Chrysohoou C, Jovovic L, Prokšelj K, Simkova I, Babazade N, Siller-Matula J, Chikhi F, Kovačević-Preradović T, Srbinovska E, Johnson V, Farrero M, Moharem-Elgamal S, Gimelli A; Pink International Young Academy of Cardiology. Women leaders in Cardiology. Contemporary profile of the WHO European region. Eur Heart J Open 2021.
- Cremer PC, Sheng CC, Sahoo D, Dugar S, Prada RA, Wang TKM, Hassan OKA, Hernandez-Montfort J, Wolinsky DA, Culver DA, Rajendram P, Duggal A, Brennan DM, Wolski KE, Lincoff AM, Nissen SE, Menon V; the Three C study group. Double-blind randomised proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation. *Eur Heart J Open* 2021.
- Ridker PM. Targeting cytokine storm in COVID-19: what have we learned? Eur Heart J Open 2021.
- Marchandot B, Curtiaud A, Trimaille A, Sattler L, Grunebaum L, Morel O. Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions. *Eur Heart J Open* 2021.